Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.
BACKGROUND
Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of de novo and recurrent bladder cancer.


OBJECTIVE
To identify a highly sensitive and specific biomarker candidate set with potential clinical utility in bladder cancer.


METHODS
Urinary biomarker concentrations were determined by ELISA. The performance of individual markers and marker combinations was assessed using ROC analysis.


RESULTS
A five-biomarker panel (IL8, MMP9, VEGFA, PTGS2 and EN2) was defined from the candidate set.


CONCLUSIONS
This panel showed a better overall performance than the best individual marker. Further validation studies are needed to evaluate its clinical utility in bladder cancer.
a AXO Science SAS , Lyon , France .
Marine
M
De Paoli
Paul
P
Perco
Irmgard
I
Mühlberger
Arno
A
Lukas
Hardev
H
Pandha
Richard
R
Morgan
Gui Jie
GJ
Feng
Christophe
C
Marquette
D014408:Biomarkers, Tumor / Q000652:urine*; D006801:Humans; D008954:Models, Biological; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine
D014408:Biomarkers, Tumor
Biomarkers; bladder cancer; invasiveness; recurrence